Literature DB >> 21337123

Mind-mapping for lung cancer: towards a personalized therapeutics approach.

N Mollberg1, M Surati, C Demchuk, R Fathi, A K Salama, A N Husain, T Hensing, R Salgia.   

Abstract

There were over 220,000 people diagnosed with lung cancer and over 160,000 people dying of lung cancer during 2010 alone in the United States. In order to arrive at better control, prevention, diagnosis, and therapeutics for lung cancer, we must be able to personalize the approach towards the disease. Mind-mapping has existed for centuries for physicians to properly think about various "flows" of personalized medicine. We include here the epidemiology, diagnosis, histology, and treatment of lung cancer-in particular, non-small cell lung cancer. As we have new molecular signatures for lung cancer, this is further detailed. This review is not meant to be a comprehensive review, but rather its purpose is to highlight important aspects of lung cancer diagnosis, management, and personalized treatment options.

Entities:  

Mesh:

Year:  2011        PMID: 21337123      PMCID: PMC3077059          DOI: 10.1007/s12325-010-0103-9

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  112 in total

1.  Associations between duration of illicit drug use and health conditions: results from the 2005-2007 national surveys on drug use and health.

Authors:  Beth Han; Joseph C Gfroerer; James D Colliver
Journal:  Ann Epidemiol       Date:  2010-02-19       Impact factor: 3.797

2.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications.

Authors:  B C McCaughan; N Martini; M S Bains; P M McCormack
Journal:  J Thorac Cardiovasc Surg       Date:  1985-06       Impact factor: 5.209

4.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

Authors:  N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara
Journal:  JAMA       Date:  1994-11-16       Impact factor: 56.272

5.  Does the mind map learning strategy facilitate information retrieval and critical thinking in medical students?

Authors:  Anthony V D'Antoni; Genevieve Pinto Zipp; Valerie G Olson; Terrence F Cahill
Journal:  BMC Med Educ       Date:  2010-09-16       Impact factor: 2.463

6.  Mediastinal nodal involvement and the prognosis of non-small cell lung cancer.

Authors:  Y Watanabe; Y Hayashi; J Shimizu; M Oda; T Iwa
Journal:  Chest       Date:  1991-08       Impact factor: 9.410

7.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

Review 8.  Who is at high risk for lung cancer? Population-level and individual-level perspectives.

Authors:  Anthony J Alberg; Jill Nonemaker
Journal:  Semin Respir Crit Care Med       Date:  2008-06       Impact factor: 3.119

9.  Positron emission tomography in staging early lung cancer: a randomized trial.

Authors:  Donna E Maziak; Gail E Darling; Richard I Inculet; Karen Y Gulenchyn; Albert A Driedger; Yee C Ung; John D Miller; Chu-Shu Gu; Kathryn J Cline; William K Evans; Mark N Levine
Journal:  Ann Intern Med       Date:  2009-07-06       Impact factor: 25.391

10.  Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON).

Authors:  K A M van den Bergh; M L Essink-Bot; G J J M Borsboom; E Th Scholten; M Prokop; H J de Koning; R J van Klaveren
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more
  9 in total

1.  U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

Authors:  Sean Khozin; Gideon M Blumenthal; Xiaoping Jiang; Kun He; Karen Boyd; Anthony Murgo; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2014-05-27

2.  Use of mind maps and iterative decision trees to develop a guideline-based clinical decision support system for routine surgical practice: case study in thyroid nodules.

Authors:  Hyeong Won Yu; Maqbool Hussain; Muhammad Afzal; Taqdir Ali; June Young Choi; Ho-Seong Han; Sungyoung Lee
Journal:  J Am Med Inform Assoc       Date:  2019-06-01       Impact factor: 4.497

3.  A novel classification of lung cancer into molecular subtypes.

Authors:  Lisandra West; Smruti J Vidwans; Nicholas P Campbell; Jeff Shrager; George R Simon; Raphael Bueno; Phillip A Dennis; Gregory A Otterson; Ravi Salgia
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

Review 4.  Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis.

Authors:  Sarada Preeta Kalainayakan; Keely E FitzGerald; Purna Chaitanya Konduri; Chantal Vidal; Li Zhang
Journal:  Cell Biosci       Date:  2018-11-02       Impact factor: 7.133

5.  [Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].

Authors:  Lan Shao; Wei Hong; Lei Zheng; Chunxiao He; Beibei Zhang; Fajun Xie; Zhengbo Song; Guangyuan Lou; Yiping Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-05

6.  [Relationship between EGFR, ALK Gene Mutation and Imaging 
and Pathological Features in Invasive Lung Adenocarcinoma].

Authors:  He Yang; Zicheng Liu; Hongya Wang; Liang Chen; Jun Wang; Wei Wen; Xinfeng Xu; Quan Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20

7.  Gene expression profiling analysis of lung adenocarcinoma.

Authors:  H Xu; J Ma; J Wu; L Chen; F Sun; C Qu; D Zheng; S Xu
Journal:  Braz J Med Biol Res       Date:  2016-02-02       Impact factor: 2.590

Review 8.  [Advances of molecular subtype and targeted therapy of lung cancer].

Authors:  Lan Shao; Zhengbo Song; Yiping Zhang; Dan Su
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-09

Review 9.  [Driver genes and its clinical significance in non-small cell lung cancer].

Authors:  Yuequan Shi; Xianghong Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-06-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.